Latest / Applied Clinical Trials
ACT Brief: AI Governance Lag, Site Payment Experience, and Schizophrenia Relapse Prevention
In today's ACT Brief, we examine governance inertia when AI accelerates protocol development, why payment experience is becoming a competitive differentiator for sites, and FDA approval of Caplyta for relapse prevention in schizophrenia.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.